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Aims Recent evidence suggests that cardiac progenitor cells (CPCs) may improve cardiac function after injury. The underlying
mechanisms are indirect, but their mediators remain unidentified. Exosomes and other secreted membrane vesicles,
hereafter collectively referred to as extracellular vesicles (EVs), act as paracrine signalling mediators. Here, we report
that EVs secreted by human CPCs are crucial cardioprotective agents.
Methods
and results
CPCs were derived from atrial appendage explants from patients who underwent heart valve surgery. CPC-conditioned
medium (CM) inhibited apoptosis in mouse HL-1 cardiomyocytic cells, while enhancing tube formation in human umbil-
ical vein endothelial cells. These effects were abrogated by depleting CM of EVs. They were reproduced by EVs secreted
by CPCs, but not by those secreted by human dermal fibroblasts. Transmission electron microscopy and nanoparticle
tracking analysis showed mostEVs to be 30–90 nm in diameter, the size of exosomes, although smaller and larger vesicles
were also present. MicroRNAs most highly enriched in EVs secreted by CPCs compared with fibroblasts included miR-
210, miR-132, and miR-146a-3p. miR-210 down-regulated its known targets, ephrin A3 and PTP1b, inhibiting apoptosis in
cardiomyocytic cells. miR-132 down-regulated its target, RasGAP-p120, enhancing tube formation in endothelial cells.
Infarctedhearts injectedwithEVs fromCPCs, butnot fromfibroblasts, exhibited less cardiomyocyte apoptosis, enhanced
angiogenesis, and improved LV ejection fraction (0.8+ 6.8 vs. 221.3+4.5%; P, 0.05) compared with those injected
with control medium.
Conclusion EVs are the active component of the paracrine secretion by human CPCs. As a cell-free approach, EVs could circumvent
many of the limitations of cell transplantation.
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1. Introduction
Ischaemic heart disease and ensuing heart failure are leading causes
of morbidity and mortality worldwide. An extensively investigated
approach for ischaemic heart disease is cell transplantation. Multiple
cell sources including bone marrow,1 adipose tissue,2 skeletal
myoblasts,3 and cardiac progenitor cells (CPCs)4 have been evaluated
in both animal models and humans. Clinical trials of autologous BM
cell transplantation in patients after acute myocardial infarction (MI)
have provided mixed results, with an overall modest improvement in
cardiac function.5 Intramyocardial injection of CPCs isolated from
adult hearts improved cardiac function in animal models of MI.6 –8
Although both direct cell differentiation and indirect mechanisms,
such as secreted growth factors and cytokines, have been implicated
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in the therapeutic benefit, accumulating evidence suggests predominant
roles of the paracrine secretion by CPCs.8 This concept is supported
by the observation that CPC-conditioned medium (CM) protects
cardiomyocytes against stress-induced apoptosis, while stimulating
tube formation in endothelial cells in vitro.8– 11 The CADUCEUS trial
of cardiosphere-derived cells has shown that some degree of cardiac
regeneration in injured hearts may be possible. The mechanism of
benefit was thought to be indirect.4
A key component of paracrine secretion in many cell types are extra-
cellular vesicles (EVs), particularly its exosomal fraction. Exosomes are
40–90 nm-sized particles stored intracellularly in endosomal compart-
ments, which are secreted when these structures fuse with the plasma
membrane.12,13 Conventional surface markers of exosomes include the
tetraspanin family members, CD9, CD63, and CD81, among others. Exo-
somes carry proteins, lipids, and nucleic acids including DNA, mRNAs,
and microRNAs (miRNAs), which they can shuttle to recipient cells,
even at a distance. miRNAs are 18–25 nucleotide, non-coding RNAs
that regulate gene expression through post-transcriptional repression.
Transfer of mRNAs and miRNAs through exosomes has emerged as a
crucialmechanismofgenetic exchangebetweencells.14,15 Non-exosomal
EVs ariseby distinct mechanisms including direct budding fromthe plasma
membrane. While non-exosomal EVs are typically larger than exosomes,
exosome purification remains a challenging task. As a result, exosomal
preparations used in many studies showed limited purity.16
Exosomes were identified as the active component of the proangio-
genic paracrine activity of bone marrow CD34+ stem cells.17 Moreover,
exosomes secreted by mesenchymal stem cells (MSCs) and mouse
CPCs mitigated tissue damage and ventricular remodelling in animal
models of myocardial ischaemia and reperfusion injury.18,19 However,
exosomes secreted by human CPCs have not been characterized yet.
Using transmission electron microscopy, we recently provided ultra-
structural evidence of exosomes and EVs secretion by human CPCs.20
Here, we report that EVs are the active component of the paracrine se-
cretion by human CPCs. Transmission electron microscopy and nano-
particle tracking analysis showed most EV secretion by CPCs to be
30–90 nm in diameter, suggesting they were exosomes, although
smaller and larger vesicles were also present. Moreover, the purified
particles expressed conventional exosomal markers including CD63.
These results suggest that exosomes were the predominant component
of the particles purified from CM-CPC. To stress their heterogeneity,
however, we hereafter refer to them as EVs. These EVs mitigated apop-
tosis triggered by serum deprivation in the neonatal mouse HL-1 cardi-
omyocytic cell line, while stimulating tube formation in human umbilical
vein endothelial cells (HUVECs), an indicator of angiogenic activity. In
vivo, injection of EVs secreted by CPCs into the infarct border zone
reduced cardiomyocyte apoptosis and scar, increased both viable
mass in the infarct area and blood vessel density, and prevented the
early impairment of ventricular function in a rat model of acute MI.
EVs secreted by normal human dermal fibroblasts (NHDFs) lacked
these beneficial effects, supporting the concept that functional activities
of EVs depend on the parent cell.17 A comparison of the miRNA tran-
scriptional profile of EVs secreted by CPCs with that of EVs secreted
by NHDFs identified several miRNAs as being particularly enriched in
the former, including miR-210, miR-132, and miR-146a-3p. Because car-
dioprotective roles of miR-210 and a role for miR-132 in vascular re-
modelling have been reported,21,22 we focused on the functional
activities of these miRNAs. Both miR-210 and miR-132 protected
HL-1 cardiomyocytic cells against apoptosis. In addition, miR-132 pro-
moted the formation of endothelial tube. These results suggest that
EVs secreted by CPCs may impart cardiac protection and the underlying
mechanism may involve miRNAs.
2. Methods
2.1 Cell sources
Human right atrial appendage specimens were obtained from patients
(n ¼ 22) who underwent surgical repair of heart valve disease and had no
concomitant coronary artery disease. The study was approved by the local
Ethical Committee and performed according to the Declaration of Helsinki.
All patients gave written informed consent to the collection of atrial speci-
men. Using the primary ex vivo tissue culture technique,6–8 the cellular out-
growth of atrial explants was collected within 14 days and seeded into
fibronectin-coated 25 mL flasks. EVs were purified from CPCs after two
passages in culture. NHDFs were purchased from Life Technologies.
2.2 EV purification methods
Medium conditioned by CPCs (CM-CPC) or NHDFs was obtained by cul-
turing cells in basal medium (BM), a 1 : 1 mix of Iscove’s Modified Dulbecco’s
Media and Dulbecco’s Modified Eagle’s Medium (Gibco) supplemented with
1% human serum albumin, for 48 h, followed by centrifugation at 3000 g for
15 min, filtration through a 0.2 mm membrane (BD Biosciences), and pro-
cessing using one of the following methods: (i) ExoQuickTM precipitation
solution (System Biosciences; SBI); (ii) ultracentrifugation at 100 000 g for
90 min; and (iii) column precipitation using Exo-spinTM kits (Cell Guidance
Systems, Cambridge, UK). The EV pellet was re-suspended in 100–
500 mL of phosphate-buffered saline (PBS; pH 7.4) and stored at 2808C.
Nanoparticle tracking analysis was performed using NanoSight LM10
(Malvern Instruments, Worcestershire, UK). CD63 and CD81 protein
levels in EVs were determined by western blotting. Protein lysate was
obtained by re-suspending EV pellet in 100 mL of RIPA buffer (Sigma).
Antibodies were purchased from SBI. Total proteins were measured using
BCA kits (Thermo Fisher Scientific).
2.3 Transmission electron microscopy
The ultrastructure of EVs was analysed using transmission electron micros-
copy, as described previously.23 Briefly, re-suspended EV pellet (3 mL) was
fixed with 2.5% glutaraldehyde, post-fixed in buffered 1% OsO4 with 1.5%
K4Fe(CN)6, embedded in 1% agar, and processed according to the standard
Epon812 embedding procedure. EVs were visualized on thin sections
(60 nm) using a Morgagni 268 transmission electron microscope (FEI
Company, The Netherlands) at 80 kV.
2.4 Flow cytometry
Surface markers expressed on CPCs and EVs were analysed by flow cytome-
try. Microbeads coated with anti-CD63 antibody (Life Technologies) were
used in EV analyses. Phycoerythrin (PE)-conjugated antibodies against
surface markers expressed on CPCs or MSCs (CD90, CD105, CD140,
CD146, CD166, CD172, and NG2 proteoglycan; all from Beckman
Coulter) or conventional exosomal markers (CD9, CD63, and CD81; all
from BD Biosciences) were used. Beads incubated with an antibody in the
absence of EVs served as a control. To assess dynamic trafficking of CD63
to exosomes, CPCs were transfected with pCT-CD63-GFP vector (Cyto-
Tracer; SBI) expressing a CD63-GFP fusion, using lipofectamine. Analyses
were performed on a MACS-Quant flow cytometer (Miltenyi Biotec).
2.5 EV uptake by HL-1 cardiomyocytic cells
To assess EV uptake by HL-1 cardiomyocytic cells, EVs from CPCs were la-
belled with DiI. Excess dye was removed by precipitation of EV. Cells cul-
tured in complete Claycomb medium24 (Sigma), hereafter referred to as
growth medium (GM)-FBS, were incubated with DiI-labelled EVs. After
12 h, cells were imaged using a Nikon C2 Plus confocal microscope. RNA
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extraction, reverse transcription, and real-time PCR protocols were used as
described in Supplementary material online, to determine intracellular
concentrations of miR-210 and miR-132 in HL-1 cells exposed to EV-
CPC. In the time-course experiment, 100 mg of EV-CPC total protein
were used (n ¼ 3 experiments). Dose–response study measurements
were performed at 48 h (n ¼ 3 experiments).
2.6 In vitro apoptosis assay
To induce apoptosis in the mouse HL-1 cardiomyocytic cell line, GM-FBS
was replaced by BM for 12 h. After 12 h, medium was supplemented with
CM-CPC, EV-depleted CM-CPC (DCM), or DCM reconstituted with the
previously removed EV fraction (DCM + EV) for 36 h. Cells kept in BM
for 48 h or changed to GM-FBS after 12 h served as controls. A pooled
sample of purified EVs secretedby CPCs (EV-CPC; n ¼ 4 patients) wascom-
pared with EVs secreted by NHDF (EV-F). Viable and dead cells were stained
using double staining kits (Dojindo EU GmbH, Germany). Activation of
apoptotic pathways was detected using activated caspase-3/7 staining kits
(Life Technologies).
2.7 In vitro angiogenesis assay
To assess the angiogenic potency of CM-CPC, EV-CPC, and EV-F, HUVECs
were seeded at 3 × 104 cells/cm2 density in Matrigel (BD Biosciences). An
endothelial cell medium (Medium 200; Gibco) supplemented with 10%
FBS (ECM-FBS) served as a positive control. Images were acquired 5 h
later, and tube length was measured using the ImageJ software (National
Institutes of Health, USA).
2.8 miRNA analyses
Total RNA was isolated from EV-CPC and EV-F using Quanti-miR kits (SBI).
Real-time PCR was performed with Advanced SYBR Green kits (Bio-Rad)
using a multistep approach. In a first step, 384 miRNAs were measured in
total RNA from a pooled EV-CPC sample (n ¼ 4 patients) using synthetic
‘spike-in’ miRNA sequences, provided with the kits for normalization.
Fifty-two miRNAs were found to be enriched more than six-fold compared
with ‘spike-in’ miRNA sequences. In the following step, these miRNAs
were directly compared with EVs from CPCs and those from NHDFs. Four-
teen miRNAs were found to be particularly enriched in EVs from CPCs.
These miRNAs were then measured in three pooled EV-CPC samples
(n ¼ 4 patients each). Based on the results of this analysis, 7 of 14 miRNAs
were then measured in EV-CPC samples from individual patients (n ¼ 6).
Data were normalized for the geometric mean of miR-U6 and RNU-6B
values and shown as 22DDCt values. Among the most highly enriched
miRNAs in EVs secreted by CPCs, miR-210 and miR-132 were chosen for
functional studies, owing to their proposed roles in cardioprotection and
vascular remodelling.21,22 Cells were transfected with miR-210 and
miR-132 mimics, or siRNAs specific for these miRNAs, using RNAiMAXTM
(Life Technologies). Expression of the miR-210 targets, ephrin A3, PTP1b,
and FLASH/CASP8AP2,21,25,26 as well as those of miR-132 target,
RasGTPase-activating protein (RasGap)-p120,22 was measured by western
blot using antibodies from Santa Cruz Biotech.
2.9 In vivo myocardial infarction
Experimental protocols were approved by the Animal Care Committee of
the Italian Ministry of Health, in accordance with Italian (DL-116, 27
January1992) and international lawsand policies (European Economic Com-
munity Council Directive 86/609, OJL 358, 12 December 1987). Animal
studies were performed as previously described.27 Briefly, acute MI was
induced in healthy male Wistar rats (250–300 g body weight), anaesthetized
with a cocktail of tiletamine and zolazepam (Zoletil 100, Virbac, France;
dosage 40 mg/kg IP), intubated, and ventilated. The left anterior descending
coronary artery was permanently ligated near its origin with a 6-0 Prolene
suture. After 60 min, the viable myocardium bordering the LV infarct zone
was injected at three different sites with a total of 150 mL of one of the
following solutions: PBS (n ¼ 9), 30 mg of EV-CPC (n ¼ 9), 300 mg of
EV-CPC (n ¼ 10), and 300 mg of Exo-F (n ¼ 4). The sham-operated group
included nine animals. At Day 7, rats were anaesthetized with Zoletil 100
(40 mg/kg) and sacrificed with iv KCl (1–2 mEq/kg) to induce diastolic
arrest of cardiac activity.
2.10 Echocardiography
Echocardiography was performed in rats sedated by IP tiletamine (29 mg/kg)
plus xylazine (4.3 mg/kg). Transthoracic echocardiography was performed
on Day 2 (baseline) and Day 7 post-MI using the MyLab 30 echocardiography
system (Esaote, Italy), equipped with a 12 MHz linear transducer, as
described previously.28 Under electrocardiographic monitoring of heart
rate, the hearts were imaged in 2D long-axis views at the level of the
highest LV diameter. LV end-diastolic and end-systolic diameters (LVEDD/
LVESD), end-diastolic wall thickness (LVEDTHK-BZ) and end-systolic wall
thickening in the border zone (LVESTK-BZ), and LV ejection fraction
(LVEF) were measured from 2D long-axis views taken through the infarcted
area. Changes in LVEF were calculated as LVEF (Day 7)2 LVEF (baseline)/
LVEF (baseline).
2.11 Histology
Rats were sacrificed at Day 7 after MI. For immunohistochemistry, hearts
were cryopreserved in optimal cutting temperature compound (Sigma) at
2808C. For morphometry, they were embedded in paraffin and cut at
8 mm thin sections. Apoptotic cardiomoycytes were detected by TUNEL
assay using In Situ Cell Death Detection kits (Roche) and a monoclonal anti-
body against a-sarcomeric actinin (a-SA; Sigma).7 From the Masson’s
trichrome-stained images (HT15 Trichrome Stain kit; Sigma), viable tissue
and scar area within the infarct region were measured on each section by
tracing the infarct borders manually using the ImageJ software. Six sections
were analysed per heart. Newly formed blood vessels were counted as
SMA+/isolectin-IB42 (Sigma) structures under the microscope.
2.12 Statistical analysis
Unless otherwise stated, results are presented as means+ SEM of n inde-
pendent experiments. Statistical analyses were performed using InStat,
version 3.0 (GraphPad Software, Inc.). The assumption that data were
sampled from populations with identical SDs was tested using the method
of Bartlett. One-way analysis of variance (ANOVA) with subsequent post
hoc multiple comparison (Tukey–Kramer multiple comparisons test and
Kruskal–Wallis test for parametric and non-parametric comparisons,
respectively) was performed. Differences with a P-value of ,0.05 were
considered statistically significant.
3. Results
3.1 Exosomes are the predominant
component of EVs
Purified particles from CM-CPC using the ExoQuickTM method were
studied by transmission electron microscopy and found to be 72.8+
20.8 nm in diameter. Many of them exhibited bi-layer membranes
(Figure 1B–BI). Nanoparticle tracking analyses of purified EVs from
CPCs using ExoQuickTM, ultracentrifugation, or Exo-spinTM revealed
modal particle sizes (range; nm) of 73 nm (40–250), 85 nm (50–400),
and 68 nm (40–400), respectively (Figure 1C–E), and concentrations
(×108 particles/mL) of 9.8, 7.2, and 4.3, respectively. The ExoQuickTM
method yielded higher CD63 and CD81 protein levels compared with
the othermethods (Figure1H). Flow cytometric analyses of EVs secreted
by CPCs revealed the expression of conventional exosomal markers
(CD63, CD9, and CD81; Figure 1F and G) along with MSC/stromal
markers (CD105, CD90, CD146, CD172, and NG2) also expressed
L. Barile et al.532
Figure 1 (A) Transmission electron micrographs showing EVs (dotted circle) secreted by human CPCs (EV-CPC) in culture. (B) Purified EVs showing a
characteristic lipid bi-layer membrane (BI: higher-magnification view). (C) Nanoparticle tracking analysis of EVs purified using ExoQuickTM precipitation
solution. (D) EVs purified by ultracentrifugation. (E) EVs purified by Exo-spinTM column precipitation. (F) Flow cytometric analysis of EVs secreted by
CPCs. Left panel: side/forward scatter (SS/FS) plot of CD63-immunobeads in the absence of antibody and EVs; gating on single beads (red dots within
the circle; higher FS values are from bead aggregates). Mid panels: control (anti-CD63 antibody; no EVs). Right panels: EVs with PE-conjugated
anti-CD63 Ab. (G) Quantitative analysis of surface marker expression on EV-CPC (mean+ SEM; n ¼ 3 experiments). (H) CD63 and CD81 western
blots for EV-CPC purified using each of the aforementioned methods.
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on parent CPCs (see Supplementary material online, Figure S1). Further-
more, dynamic trafficking of CD63 to exosomes was visualized in EVs
secreted by CPCs transfected with the CD63-GFP vector (see Supple-
mentary material online, Figure S2). Taken together, these results indi-
cate that exosomes are the predominant component of EVs secreted
by CPCs. With respect to the degrees of exosomal purity achieved by
the three methods used, ExoQuickTM was comparable with, or slightly
better than, ultracentrifugation and Exo-spinTM. However, a thorough
comparison of purification methods was beyond the scope of this study.
3.2 EVs are the active component
of CM-CPC
Anti-apoptotic activities of CM-CPC were assessed in the HL-1 cardio-
myocytic cell line after 48 h of serum deprivation (Figure 2A). CM-CPC
added at 12 h reduced dead cells to 40+ 8% compared with 72+9%
in the control group (P, 0.05; Figure 2B). EV-depleted CM-CPC
(DCM) did not reduce the number of dead cells (72+ 6%; NS). Recon-
stituting DCM with the previously removed EV fraction (DCM + EV)
restored anti-apoptotic activity, reducing dead cells to 44+ 5% (P,
0.05 vs. BM). Similar changes were found in cells positive for activated
caspase-3/7, a marker of programmed cell death activation (Figure 2C).
Analogously, CM-CPC and DCM + EV, but not DCM, stimulated tube
formation in HUVECs (Figure 2D). We then compared purified EVs
secreted by CPCs with those secreted by fibroblasts. Only the former
inhibited starvation-induced apoptosis in the HL-1 cardiomyocytic cell
line, while stimulating tube formation in HUVECs (Figure 3). These
results demonstrate that EVs are the active component of CM-CPC,
and that functional activities of EVs depend on the parent cell type.
3.3 EVs secreted by CPCs are taken up by
cardiomyocytes and impact on intracellular
miRNA concentrations
Using laser confocal microscopy, we provided qualitative evidence that
HL-1 cardiomyocytic cells take up DiI-labelled EVs secreted by CPCs
(Figure 4A–F ). miRNA analyses revealed that miRNA-210 and
miRNA-132 were among the most highly enriched miRNAs in EVs
secreted by CPCs compared with those secreted by fibroblasts
(Figure 4G and see Supplementary material online, Figure S3). Incubation
of these cells with EVs from CPCs resulted in a time anddose-dependent
increase in the intracellular concentrations of miRNA-210 and
miRNA-132 (Figure 4H). This observation plausibly reflects EV-mediated
miRNA transfer to these cells.
3.4 EVs secreted by CPCs are enriched
in miRNAs with anti-apoptotic and
proangiogenic activities
miRNA transcriptional profiling of EVs secreted by CPCs or fibroblasts
identified several miRNAs that were enriched in the former, such as
miR-210, miR-132, miR-146a-3p, and miR-181 (see Supplementary ma-
terial online, Figure S3). Functional roles were studied for two of them:
miR-210 and miR-132. Both of these miRNAs inhibited apoptosis in
HL-1 cardiomyocytic cells (Figure 5A). Conversely, transcriptional silen-
cing of miR-210 exacerbated apoptosis (a similar trend was observed for
miR-132). The effect of miR-210 was associated with functional down-
regulation of its known targets, ephrin A3 and PTP1, but not FLASH/
CASP8AP2 (Figure 5B and C ). miR-132 promoted tube formation in
HUVECs (Figure 5D). This effect was associated with functional down-
regulation of its known target, RasGap-p120 (Figure 5E and F ). These
results demonstrate that EVs secreted by CPCs are enriched in
miRNAs with anti-apoptotic and proangiogenic activities. These
miRNAs include miR-210 and miR-132.
3.5 EVs secreted by CPCs improve cardiac
function after MI in vivo
Functional effects of EVs secreted by CPCs were assessed using an in vivo
model of acute MI. Echocardiographic data are shown in Figure 6. Heart
rate was similar with all treatments (not shown). Each group of operated
rats showed decreased LVEF, both at baseline and at 7 days, compared
with sham-operated animals. LVEF at baseline was comparable in all
groups except sham-operated animals. In PBS-injected hearts, LVEF sig-
nificantlydecreased frombaseline today7. Infarcted hearts injected with
either dosage of EVs secreted by CPCs, but not those injected with EVs
secreted by fibroblasts, showed a higher LVEF at 7 days compared with
the PBS-injected control group (P, 0.05). LVEF decreased from base-
line to Day 7 in hearts injected with PBS, EV-F, or the lower dosage
of EV-CPC, whereas it slightly increased in those injected with the
higher dosage of EV-CPC (0.8+ 6.8 vs. 221.3+4.5% in the PBS
group; P, 0.05). The increase in LV diameters observed by Day 7 in
the PBS and EV-F groups was prevented by either dosage of EV-CPCs.
Systolic LV wall thickening in the infarct border zone was enhanced
with either dosage of EV-CPC (P, 0.05), but not with EV-F. These
results indicate that EVs secreted by CPCs, but not those secreted by
fibroblasts, improve cardiac function after MI.
3.6 EVs secreted by CPCs inhibit
cardiomyocyte apoptosis, reduce scar,
and promote angiogenesis after MI
We analysed the morphological consequences of EV injection on
scarred areas, cardiomyocyte apoptosis, and blood vessel density in
infarcted hearts. Histological analyses showed significantly larger areas
of viable tissue in the infarct zone in hearts injected with the higher or
lower dosage of EVs secreted by CPCs (41+ 8 and 32+5%, respect-
ively), compared with those receiving EVs secreted by fibroblasts
(24+1%; P, 0.05) or PBS control medium (23+2%; P, 0.05;
Figure 7A and B). Reciprocally, scarred areas were decreased in hearts
injected with the higher dosage of EVs from CPCs (59+8 vs. 77+
2% in the PBS group; P, 0.05; Figure 7A and C). TUNEL-positive apop-
totic cardiomyocytes were significantly decreased (P, 0.05; Figure 7D),
while blood vessel density being increased in hearts injected with EVs
secreted by CPCs (84+13 vs. 34+ 5 vessel per mm2 in the PBS
group; P, 0.01; Figure 7E). These findings demonstrate structural ben-
efits of EVs secreted by CPCs and delivered to injured hearts in vivo.
4. Discussion
Recent evidence suggests that CPC transplantation into damaged hearts
may be beneficial, and that indirect mechanisms may be responsible for
most of the therapeutic benefit. Because EVs are increasingly emerging
as the active component of the paracrine secretion by various cell
types,17,18 we have investigated their potential role as mediators of
the cardioprotective effect of human CPCs. Here, we show that EVs
fully account for the cardioprotective and proangiogenic paracrine activ-
ities of human CPCs. Indeed, CM-CPC depleted of EVs lacked these
activities, which were recapitulated by purified EVs. This observation
would imply negligible roles for soluble factors secreted by CPCs,
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Figure2 (A) In vitro apoptosis assay protocol: in HL-1 cardiomyocytic cell cultures, growth medium (GM-FBS) was changed to serum-free basal medium
(BM) at T0. After 12 h starvation (T12 h), BM was either replaced by GM-FBS (control) or supplemented with one of the followings: CM-CPC,
CPC-conditioned medium; DCM, EV-depleted CM; or DCM + EV, DCM reconstituted with the previously removed EV fraction. (B) Dead (red) and
viable cells (green) in the different study groups. (C) Immunostaining for activated caspase 3/7 (green); nuclear counterstaining with DAPI (blue). Quan-
titative data are fractions (mean+ SEM) of dead and activated caspase 3/7-positive cells (n ¼ 4 experiments; *P, 0.05 vs. BM; **P, 0.01 vs. BM;
#P, 0.05 vs. DCM using the parametric Tukey–Kramer multiple comparison test). (D) In vitro angiogenesis assay. Photomicrographs showing tube for-
mation in HUVECs under the above conditions (ECM-FBS, endothelial cell medium; reference bars, 0.1 mm).
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such as growth factors and cytokines, which are not encapsulated in
membrane vesicles, possibly due to enzymatic degradation in the extra-
cellular compartment. In contrast, membrane vesicles protect their
cargoes and deliver them to recipient cells.
Collectively, transmission electron microscopy, nanoparticle tracking
analysis, and surface antigen expression data indicated that the purified
particles from human CPCs predominantly consists of exosomes.
Taking into account the presence of particles .90 nm in diameter in
the purified preparations, however, we refer to them as EVs, which
encompasses both exosomal and non-exosomal EVs. It should be
stressed that many studies of ‘exosomes’ have actually used heteroge-
neous EV populations. One notable exception was the study by Lai
et al.,18 who purified exosomes secreted by MSCs as a homogeneous
population of particles with a hydrodynamic radius of 55–65 nm by
size-exclusion fractionation on a HPLC. These particles reduced
infarct size in an ex vivo mouse Langendorff heart model of myocardial
ischaemia/reperfusion injury.
When injected into the infarct border zone in vivo, purified EVs
secreted by CPCs mitigated cardiomyocyte apoptosis, augmented
blood vessel density, reduced scar while increasing viable areas in the
infarct zone, and improved cardiac function compared with hearts
injected with control medium. In contrast, purified EVs secreted by
dermal fibroblasts lacked therapeutic benefits, illustrating the critical
role of the parent cell. These findings are in line with, and expand, the
aforementioned data by Lai et al.18 on exosomes secreted by MSCs,
as well as data by Chen et al.,19 showing anti-apoptotic activity of exo-
somes secreted by mouse CPCs in a myocardial model of ischaemia/
reperfusion injury.
EVs secreted by CPCs were enriched in several miRNAs including
miR-210, miR-132, and miR-146a-3p compared with those secreted
by fibroblasts. Both miR-210 and miR-132 inhibited apoptosis in the
HL-1 cardiomyocytic cell line in vitro. This effect of miR-210 was asso-
ciated with functional down-regulation of its validated targets, ephrin
A3 and PTP1, but not of FLASH/CASP8AP2. These results are in line
with previous findings.21 Moreover, miR-132 stimulated tube formation
in HUVECs. This effect was associated with functional down-regulation
of the known miR-132 target, RasGap-p120. This observation is in
agreement with previous data.22 We also documented dose- and
Figure3 (A) In vitro angiogenesis assay using purified EVs. EVs secreted by CPCs (EV-CPC) promote endothelial tube formation, whereas those secreted
by fibroblasts (EV-F) do not (mean+ SEM; n ¼ 7 experiments; *P, 0.05 vs. BM; #P, 0.05 vs. EV-F using the parametric Tukey–Kramer multiple com-
parison test; ECM-FBS, endothelial cell medium). (B) In vitro apoptosis assay using serial dilutions of purified EV-CPV and EV-F, showing dose-dependent
inhibition of apoptosis by EV-CPV, but not EV-F. Quantitative data are fractions of the HL-1 cardiomyocytic cells staining positive for activated caspase-3/7
(mean+ SEM; n ¼ 4 experiments; *P, 0.05; **P, 0.01; ***P, 0.001 vs. EV-F using the parametric Student’s t-test; reference bars, 0.1 mm).
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Figure 4 Uptake of EVs from CPCs (EV-CPC) by HL-1 cardiomyocytic cells and changes in the intracellular concentrations of some of the miRNAs
enriched in EV-CPC. (A andB) Fluorescence/light photomicrographs of DiI-labelled EV-CPC (red dots) taken up by cardiomyocytic cells. (C) Laser confocal
photomicrograph showing DAPI-stained nuclei (blue). (D) Cells visualized with calcein (green). (E) DiI-labelled EV-CPC (red dots). (F) High-magnification
merge (white arrow indicates an intracellular EV-CPC aggregate; red arrows indicate the same EV-CPC aggregate depicted in two orthogonal axes, verifying
its intracellular location on both axes). (G) Relative expression of miR-210 and miR-132 in EV-CPC compared with EV-F (mean+ SEM; n ¼ 6 experiments;
*P, 0.05 using the parametric Tukey–Kramer multiple comparison test). (H)Intracellular concentrations of miR-210 and miR-132 in HL-1 cells exposed
to EV-CPC (100 mg of total protein) for the indicated periods of time (upper panel; n ¼ 3 experiments). Lower panels: Dose–response studies (measure-
ments at 48 h; n ¼ 3 experiments).
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time-dependent increases in the intracellular concentrations of miR-210
and miR-132 after exposure of the HL-1 cardiomyocytic cell line to EVs
secretedby CPCs. This finding shows thatpurifieddonor EVscan modify
miRNA concentrations in recipient cardiomyocytes. miRNA transfer
therefore appears to be a plausible mechanism for the therapeutic
benefit of EVs.
Figure 5 Gain- and loss-of-function studies of miR-210 and miR-132, and regulation of known targets thereof. (A) Apoptotic HL-1 cardiomyocytic cells
transfected with a miR-210 and/or a miR-132 mimic, or transcriptional inhibitors thereof (si-miR-210 and si-miR-132; mean+ SEM; n ¼ 5 experiments;
*P, 0.05vs. cel-miR-39; #P, 0.05vs. BM; dP, 0.05 vs. BMand cel-miR-39usingnon-parametricDunn’smultiple comparisons test). (B)Western blots for
the miR-210 targets, ephrin A3, PTP1, and FLASH. (C) Densitometric analysis for PTP1 and ephrin A3 (n ¼ 3 experiments; a.u. ¼ arbitraryunits). (D) In vitro
angiogenesis assay. Photomicrographs showing increased tube formation in HUVECs transfected with a miR-132 mimic, but not with si-miR-132
(mean+ SEM; n ¼ 6 experiments; **P, 0.01 vs. BM; #P, 0.05 vs. miR-132; dP, 0.01 vs. miR-132 using the parametric Tukey–Kramer multiple
comparison test; dimensional bars, 100 mm). (E) Western blot for RasGap-p120. (F) Densitometric analysis of RasGap-p120 (n ¼ 3 experiments;
a.u. ¼ arbitrary units).
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Figure 6 Echocardiographic results at baseline (i.e. Day 2; white bars) and at Day 7 after MI (black bars). M-mode images in the different groups at Day 7
(white arrows indicate systolic anterior wall thickening in EV-CPC–injected hearts). Changes in LVEF frombaseline to Day7 were negative in all groups, but
in hearts injected with the higher dosage (HD) in EV-CPC (LD, lower dosage; LVEDD/LVESD, LV end-diastolic/end-systolic diameter; LVEDTHK-BZ, LV
end-diastolic wall thickness; LVESTK-BZ, end-systolic wall thickening in the border zone; mean+ SEM; PBS, n ¼ 9; 30 mg EV-CPC LD, n ¼ 9; 300 mg
EV-CPC HD, n ¼ 10; 300 mg Exo-F, n ¼ 4; sham, n ¼ 9; *P, 0.05 vs. PBS; #P, 0.05 at Day 7 vs. baseline; sP, 0.05 sham vs. PBS at Day 7 using the para-
metric Tukey–Kramer multiple comparison test).
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Figure7 Morphometric analysesof infarcted rat hearts. (A) Masson’s trichrome-stained sections of EV-CPC- (left) and PBS-injected hearts (right). (B and
C) Quantitative analyses of viable and scar areas (%) in the infarct zone. (D) TUNEL-positive (green) apoptotic cardiomyocytes (a-SA -positive cells; red).
(E) Smooth muscle actin-positive blood vessels (red). Quantitative analyses of apoptotic cardiomyocytes and vessel density (mean+ SEM; EV-F, n ¼ 4;
all other groups, n ¼ 5; HD/LD, higher/lower dosage of EV-CPC; *P, 0.05 vs. PBS; #P, 0.05 vs. EV-F using the parametric Tukey–Kramer multiple
comparison test).
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As cell-free products, EVs including exosomes may have a potential
for circumventing many of the limitations of using replicating cells as
therapeutic agents.29 Indeed, secreted vesicles may be easier to manu-
facture and standardize in terms of dosage and biological activity com-
pared with their parent cells. Exosomes are stable during storage at
2208C, and their size is unaffected by multiple freezing to 2208C and
thawing, whereas it decreases at 4 and 378C, indicating structural
changes or degradation.30 After all, there may be no interest in trans-
planting cells that essentially act through their paracrine secretion.
Further studies are needed to address long-term effects of exosome
therapy for damaged hearts and whether allogeneic cells could be
used as EV donors for clinical use.
In conclusion, we have demonstrated that EVs are the active compo-
nent of the paracrine secretion by human CPCs, areenriched in miRNAs
with anti-apoptotic and proangiogenic activities, and can improve
cardiac function after MI.
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